Sector News

Sanofi taps Bayer’s Brandicourt for CEO job

February 20, 2015
Life sciences
French pharma group Sanofi confirmed Friday it has appointed Olivier Brandicourt to be its new chief executive, four months after firing his widely-respected predecessor Chris Viehbacher.
 
Paris-educated and a French citizen, Brandicourt is seen as being more likely to avoid the kind of cultural clashes that ultimately led to the ouster of the German-Canadian Viehbacher in October. Sanofi’s board had accused Viehbacher of going behind its back with a plan for mass lay-offs in France–a politically explosive move for one of the country’s biggest employers.
 
Brandicourt also has extensive international experience, notably in the U.S., where Sanofi makes a third of its sales. He is currently head of German giant Bayer AG’s global health-care business, but spent much of his career at Pfizer Inc. He only moved to Bayer 17 months ago. Bayer has named Werner Baumann as Brandicourt’s successor at its health-care unit.
 
Despite a challenging outlook, Sanofi’s shares are testing new record highs, having more than recovered the losses that followed Viehbacher’s departure. Viehbacher had been forced out after warning that its key diabetes segment wouldn’t grow this year due to pressure from competition and to the fact that Lantus, its flagship diabetes drug, will lose patent protection in the U.S. this year.
 
By Geoffrey Smith
 
Source: Fortune

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach